This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Rousseau, P. Search for Related Content PubMed PubMed Citation Articles by Rousseau, P. Social Bookmarking                         What's this?

Antiemetic therapy in adults with terminal disease: A brief review

Geriatrics, VA Medical Center, Phoenix, Arizona, and Adult Development and Aging, Arizona State University Tempe, Arizona

Although nausea and vomiting (NV) are common complaints among individuals with terminal illness, there are few studies evaluating the magnitude of this disabling syndrome. Most research has emphasized chemotherapy-induced emesis, however, Reuben and Mor’ analyzed National Hospice Study data 2 and noted NV in 62 percent of patients with advanced malignancy during the last two months of life. In addition, NV was observed more frequently in women, persons younger than 65 years of age, and patients with stomach and breast cancer Lamentably, physicians were less likely to prescribe antiemetics in the elderly and inpatients with an impaired level of awareness.

With such a paucity of studies on NV in terminally-ill patients, there is frequent confusion regarding the etiology of emesis and the selection of appropriate antiemetics. This article will review the syndrome of N1 and discuss available drug regimens.

American Journal of Hospice and Palliative Medicine®, Vol. 12, No. 1, 13-18 (1995)
DOI: 10.1177/104990919501200108


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?